Summary Mitomycin, ifosfamide and cis-platin are three of the most active single agents in the chemotherapy of non-small cell lung cancer. We have combined them for a phase 2 study in patients with inoperable non-small cell lung cancer. The regimen ('MIC') comprised: mitomycin 6mg m -2, ifosfamide 3gm-2 and cis-platin 50mgm-2, with routine use of lorazepam, dexamethasone and high dose metoclopramide for anti-emesis. Seventy-four ambulatory patients with untreated, limited (LD) or extensive (ED) disease have entered this study, and 66 are evaluable for response. Thirty patients (45%) have achieved partial remission and 7 (11%) complete remission, as assessed radiologically. The overall response rate is thus 56% (95% confidence interval 44%-68%). There have been 29/43 responses in LD (67%, 95% CI 53%-81%) and 8/23 in ED (35%, 95% CI 15%-55%). The median response duration, measured from the start of treatment is 8.75 months. The median survival for the whole group is 9.2 months. The principal toxicity was nausea and vomiting which was severe or prolonged (>48h) for one or more courses, in 9% of patients. Performance status (PS) and weight were assessed before, and 3 weeks after the last course of chemotherapy. Fifteen (of 31 evaluable) responders improved their PS and only 1 responder deteriorated. Twenty-one of the 28 evaluable non-responders had no change in PS. The difference in PS change between responders and non-responders is highly significant (P=0.002). Thirty evaluable responders experienced a mean increase in weight of 2.9% with treatment, whereas 24 evaluable non-responders had a mean weight loss of 3.8%. This change is also highly significant (P=0.0013). MIC is clearly a well tolerated regime and among the most active combinations in non-small cell lung cancer. It will now be tested in a randomized trial against no chemotherapy.
Non-small cell lung cancer (NSCLC) is the commonest malignant disease in the western world and is among the most chemoresistant. There are only 5 drugs (ifosfamide, mitomycin, cis-platin, vinblastine and vindesine) which, when tested as single agents in large numbers, produce major responses in 15% or more of cases (Kris et al., 1985) . Mitomycin, ifosfamide and cis-platin have been associated with response rates of 20%, 26% and 20% respectively and are the 3 most active agents (Bakowski et al., 1983) . We have combined ifosfamide with mitomycin in a recent phase 2 study in NSCLC (Chetiyawardana et al., 1985) . Thirty patients were assessable for response to chemotherapy -8 achieving partial remission (PR) and 5 complete remission (CR). The overall response rate to chemotherapy was thus 43%. Cis-platin and ifosfamide have demonstrated synergism in experimental models (Goldin, 1982) . Although both agents are associated with severe nausea and vomiting, a trial of anti-emetic therapy in our unit suggested that the combination of high dose metoclopramide infusion, lorazepam and dexamethasone would allow these drugs to be combined with acceptable subjective toxicity (O'Brien et al., 1987) .
Thus in January 1986 we commenced a phase 2 study of mitomycin, ifosfamide and cis-platin (MIC) in inoperable NSCLC. In addition to assessing objective response, toxicity and survival we have systematically monitored performance status (PS) and weight. Br. J. Cancer (1988), 58, 359-361 maximum of 4 in responding patients who had not experienced unacceptable toxicity. Patients were fully reassessed after a maximum of 4 courses of chemotherapy. Response was assessed clinically and with chest X-ray in all cases using WHO criteria (WHO, 1979) . Staging investigations were repeated as appropriate.
Weight and WHO performance status were assessed before, and 3 weeks after completing chemotherapy. Survival curves were plotted using the Kaplan-Meier method and were compared by the logrank test. Changes in weight and performance status between responders and non-responders were compared using Student's t test and the Mann-Whitney U test, respectively. [37] [351 [201 [161 [51--- Figure 2 Actuarial curve of remission duration in 37 complete and partial responders to MIC, with 95% confidence intervals (dotted lines) and numbers at risk given in brackets [n] . Time (months) Figure 3 Actuarial survival curve for all 74 patients entered with 95% confidence intervals (dotted lines) and numbers at risk given in brackets [n] . (Figure 5 ), whereas 24 evaluable non-responders had a mean weight loss of 3.8%. The difference in this change was also highly significant (t,2 =3.41; P=0.0013). non-responders. The difference in weight change is highly significant (t52 =3.41; P=0.0013).
Discussion
An objective response rate of 56%, with 11% complete responses suggest that the MIC combination is among the most active yet reported in this disease. A smaller series recently reported from Madrid has shown similar results (Giron et al., 1987) . Cis-platin and mitomycin have been combined with vindesine and response rates of the same order as reported here have been seen (Kris et al., 1986 Bakker et al. (1986) reported a response rate of 48% in 28 NSCLC patients with cis-platin, vindesine and bleomycin. Performance status and weight dropped significantly during chemotherapy in both responders and non-responders. Although PS approached pretreatment scores after discontinuation of chemotherapy in the responders, the authors conclude that treatmentassociated toxicity (principally vomiting) and deterioration of the patient's well-being offset any potential survival advantage for the majority of patients. The response rate in the present study is similar but we observe important differences in these parameters. Almost half the responders improved PS, and the large majority of non-responders experienced no change. Furthermore patients who responded to MIC had a mean weight gain with 12 weeks treatment, compared to a mean loss of weight in those not responding. The difference between the 2 studies may be that MIC is more active and the responses are associated with greater clinical improvement. It may also relate to the anti-emetic regimen and cisplatin dose: domperidone 10mg every 4h as used in Bakker's study is inadequate anti-emetic therapy for full dose cis-platin chemotherapy.
The question of survival advantage conferred by chemotherapy can only be answered in a randomised trial. According to one review mitomycin, ifosfamide and cis-platin are the 3 most active single agents in NSCLC (Bakowski & Creach, 1983) , and when combined in the schedule used here, are well tolerated in the majority of patients. Objective response is associated with prompt clinical improvement in a big enough proportion of these cases to make a large scale randomised trial against no chemotherapy a worthwhile venture. We are now conducting a randomised comparison of MIC followed by radiotherapy versus radiotherapy alone in limited stage, inoperable NSCLC.
